Irvine, CA — Research published in the journalNature showed promise that nicotinamide riboside (NR) may help lower levels of amyloid deposits and improve mitochondrial energy production and memory in mice with Alzheimer’s Disease.
Dr. Johan Auwerx and colleagues at the Ecole Polytechnique Federale de Lausanne in Switzerland conducted a study to see if NR (a recently discovered vitamin and NAD+ booster) had the ability to restore the brain mitochondria, which is significantly impaired by Alzheimer’s disease.
In the brains of individuals afflicted with Alzheimer’s, the mitochondrial energy output is reduced significantly and mitochondrial stress response, which normally reuses damaged mitochondrial proteins, becomes non functioning. Dr. Auwerx and his colleagues demonstrated that the use of NR in treating Alzheimer’s is promising.
Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and the Chief Scientific Advisor of ChromaDex said in a statement “given the preclinical data and the human safety data that are coming out, we’re thrilled to have additional well vetted applications where we can test NR to improve the human condition. By combining novel imaging modalities with NAD metabolomics, we expect to see multiple opportunities to test NR as a neuroprotective agent in people in coming years.”
